B. Riley analyst Mayank Mamtani raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $236 from $194 and keeps a Neutral rating on the shares. Madrigal’s Q3 earnings “blowout” print ...
In its second full quarter on the market, the fatty liver disease drug racked up sales of $62 million, which routed Wall ...
CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor ...
Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval. Read why I maintain my buy rating ...
Zacks.com on MSN6d
Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock UpMadrigal Pharmaceuticals MDGL reported third-quarter 2024 loss of $4.92 per share, narrower than the Zacks Consensus Estimate ...
MONTCO.Today on MSN4d
Conshohocken’s Madrigal Pharmaceuticals Reports Sales Through the RoofConshohocken’s Madrigal Pharmaceuticals, saw third-quarter sales soar for its NASH treatment, Rezdiffra, writes John George ...
Novo's Rival Drug Shows Promise, But Madrigal's First-Mover Advantage Keeps Investors Hooked--What's Next for This Rising ...
In the effort to expand approaches to treating Alzheimer’s beyond targeting amyloid, some companies have sought to target ...
Sibold credited Rezdiffra's sales growth to the growing adoption of the treatment by prescribers, broader payer coverage for ...
Madrigal Pharmaceuticals Inc (MDGL) reports robust Q3 sales driven by Rezdiffra demand, while navigating increased SG&A ...
Madrigal Pharmaceuticals' Rezdiffra for NASH shows strong early demand, positioning the company as a market leader. Read why ...
Regeneron shares continued to decline on growing concerns about Eylea’s future. Elsewhere, new details emerged about Lundbeck ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback